TDB Backs GrivaVision to Boost India’s Indigenous Medtech Manufacturing in Cervical Cancer Screening

The Technology Development Board (TDB) under India’s Department of Science & Technology has partnered with Visakhapatnam-based Griva Healthcare Pvt. Ltd. to commercialize GrivaVision, an AI-powered portable colposcope designed for early detection of cervical pre-cancerous lesions.

Founded in 2025, by Nidun Jacob and Parvathi Radhakrishnan, Griva Healthcare will establish manufacturing in Kollam, Kerala, strengthening India’s domestic medtech ecosystem.

Company Overview: Griva Healthcare Pvt. Ltd.

• Founded: January 2025
• Founders/Directors: Nidun Jacob, Parvathi Radhakrishnan
• Headquarters: Visakhapatnam, Andhra Pradesh, India
• R&D Base: AIC-AMTZ Medivalley, Visakhapatnam
• Upcoming Manufacturing Hub: Kollam, Kerala
• Capital Structure: Authorized capital ₹1 lakh; paid-up capital ₹1 lakh
• Status: Active, unlisted private limited company

Technology: GrivaVision

• Device Type: Portable digital colposcope with AI-assisted capabilities
• Classification: Class B non-invasive medical device; CDSCO Class B manufacturing licence
• Standards: ISO 13485 compliant; WHO-approved Automated Visual Evaluation (AVE) standards; ABDM-compliant software
• Features: High-definition camera, in-built display, user-friendly interface, advanced optics, proprietary AI-enabled diagnostic software
• Patent: Hardware architecture patented in India by Griva Healthcare
• Localization: Over 50% of components sourced indigenously

The device is designated as a Class B non-invasive medical instrument and holds a CDSCO Class B manufacturing licence. It is being developed under ISO 13485 quality standards, ensuring compliance with international benchmarks for medical devices.

Griva Healthcare has secured a patent in India for its proprietary hardware architecture, reinforcing its innovation credentials. Currently, the company is conducting R&D at AIC-AMTZ Medivalley in Visakhapatnam, with support from TDB enabling the transition to commercial-scale manufacturing at its upcoming facility in Kollam, Kerala.

A defining aspect of the initiative is its emphasis on indigenous development and localization. More than 50% of the components are sourced domestically, underscoring India’s growing medtech capabilities. Scaling commercialization is expected to strengthen the national medical device value chain and deliver a cost-effective Indian alternative for cervical cancer diagnostics, reducing reliance on imported technologies.

Image – YouTube/GrivaHealth

Strategic Significance

• Healthcare Impact: Enables early detection of cervical pre-cancerous lesions
• Accessibility: Designed for primary and community healthcare settings
• Policy Alignment: Supports India’s self-reliance in medical technologies
• Digital Integration: ABDM-compliant software ensures compatibility with India’s digital health ecosystem
• Economic Impact: Strengthens domestic medical device value chain

Leadership & Government Statements

• Rajesh Kumar Pathak, Secretary, TDB: “Early detection can make a decisive difference in addressing cervical cancer. Indigenous technologies such as GrivaVision demonstrate how medical devices, digital health and artificial intelligence can come together to address a critical healthcare need at scale.”
• Griva Healthcare Leadership: Expressed gratitude for TDB’s support, noting that the assistance will enable transition from R&D to commercial-scale manufacturing and expand access to AI-assisted cervical cancer screening.

Quick Reference Table

Aspect	Details
Founders	Nidun Jacob, Parvathi Radhakrishnan
HQ	Visakhapatnam, Andhra Pradesh
Manufacturing	Kollam, Kerala
Device	AI-powered portable colposcope
Standards	ISO 13485, WHO AVE, ABDM-compliant
Classification	CDSCO Class B
Patent	Proprietary hardware architecture
Localization	>50% components sourced indigenously